Deep Track Biotechnology Master Fund, Ltd. - Sep 10, 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC (LBRX)

Role: 10%+ Owner
Signature: Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director
Stock symbol: LBRX
Transactions as of: Sep 10, 2025
Transactions value $: $0
Form type: 3
Date filed: 9/10/2025, 07:33 PM
Previous filing: Aug 22, 2025
Next filing: Sep 16, 2025
SEC: View on sec.gov

Reporting Owners (3)

Name	Relationship	Address	Signature	Signature date	CIK
Deep Track Biotechnology Master Fund, Ltd.	10%+ Owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVE, GEORGE TOWN, CAYMAN ISLANDS	Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director	2025-09-10	0002015536
Deep Track Capital, LP	10%+ Owner	200 GREENWICH AVE, 3RD FLOOR, GREENWICH	Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser	2025-09-10	0001856083
KROIN DAVID	10%+ Owner	C/O DEEP TRACK CAPITAL, LP, 200 GREENWICH AVE, 3RD FLOOR, GREENWICH	/s/ David Kroin	2025-09-10	0001397513

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LBRX	Series C Preferred Stock							Sep 10, 2025	Common Stock	686K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series C Preferred Stock is convertible at anytime at the option of the holder, without payment of additional consideration, into Common Stock and has no expiration date. Immediately prior to the closing of the Issuer's initial public offering, the Series C Preferred Stock will convert automatically at a conversion ratio that is dependent upon the initial price per share to the public in the Issuer's initial public offering.
F2	Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Content

Each share of Series C Preferred Stock is convertible at anytime at the option of the holder, without payment of additional consideration, into Common Stock and has no expiration date. Immediately prior to the closing of the Issuer's initial public offering, the Series C Preferred Stock will convert automatically at a conversion ratio that is dependent upon the initial price per share to the public in the Issuer's initial public offering.

Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.